Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03017690 · ClinicalTrials.gov registry record
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 22
- Enrollment target
NCT03017690 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 22 participants.
The verdict
NCT03017690 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2018-05-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03017690
The ClinicalTrials.gov registry entry for NCT03017690 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03017690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03017690 about?
NCT03017690 is a clinical study titled "Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)". An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
What is the current status of trial NCT03017690?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2017-04-12. Estimated completion is 2018-05-30.
Who is sponsoring clinical trial NCT03017690?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.